Figure 2

HBV-miR-3 is an early predictor for HBeAg seroconversion in the HBeAg-positive patients treated with PegIFN-α. (A) AUC values of HBV-miR3 at weeks 0 and 12. (B)Predictive performance of biomarker cut-off values and their combined performance. (C)Substrate analysis of HBV-miR3 level for the PegIFN-a response.